Highest-materiality recent filing
Incyte signs CMS Medicaid pricing deal for Jakafi, avoids GUARD/GLOBE mandates
Agreement with CMS enables state Medicaid access to Jakafi and Jakafi XR at prices aligned with a group of advanced industrialized nations.
Incyte Q2 revenue $1.67B (+38% YoY); raises FY2026 guidance; acquires Vega Therapeutics for $1.25B
Total net sales $1.49B (+40% YoY); GAAP diluted EPS $2.81, Non-GAAP diluted EPS $3.09.
Incyte completes $1.25B acquisition of Vega Therapeutics, adding Phase 3 VWD asset VGA039
Acquisition adds VGA039, a novel monoclonal antibody in Phase 3 for von Willebrand disease (VWD).
Incyte settles CMS dispute over Opzelura Medicaid rebates; records $246M benefit
CMS will not apply line extension regulation to Opzelura as if it were a line extension of Jakafi; Incyte withdraws lawsuit.
Incyte shareholders elect 8 directors, approve say-on-pay, ratify Ernst & Young at annual meeting
All 8 director nominees elected with overwhelming support; highest for Katherine High (172.3M for) and Edmund Harrigan (172.2M for).
Incyte to acquire Vega Therapeutics for $1.25B upfront; total up to $2.0B
Acquires Vega Therapeutics from Star Therapeutics; adds VGA039, a Phase 3 anti-Protein S mAb for von Willebrand disease.
Incyte Q1 revenue $1.27B (+21% YoY), Non-GAAP EPS $1.81 beats prior $1.16; pipeline expands
Total net sales $1.10B (+20% YoY); Jakafi $758M (+7%), Opzelura $143M (+20%), Hem/Onc $204M (+116%).
Incyte director Susanne Schaffert resigns from board effective April 15
Susanne Schaffert notified Incyte of resignation from Board on March 26, 2026.
Incyte appoints Cagnoni as President, integrates U.S. commercial; Trotta departs
Pablo Cagnoni named President, Incyte and Global Head of R&D; replaces Bill Meury as President; Meury remains CEO.
FDA issues Complete Response Letter for Incyte's Zynyz in NSCLC due to facility inspection findings
FDA CRL for Zynyz (retifanlimab) sBLA for metastatic NSCLC with platinum chemo, citing Catalent Indiana inspection findings.
Incyte Q4 total revenue $1.51B (+28% YoY); FY 2025 net product revenue beat guidance
Q4 total revenue $1.51B (+28% YoY); net product revenue $1.22B (+20%). FY 2025 net product revenue $4.35B, above $4.23-4.32B guidance.
Incyte director Hervé Hoppenot retires from board effective Dec 10, 2025
Hervé Hoppenot retired from Incyte's Board of Directors effective December 10, 2025.
Incyte Q3 revenue $1.37B (+20% YoY); raises FY 2025 product revenue guidance to $4.23-4.32B
GAAP diluted EPS $2.11 vs $0.54 YoY; Non-GAAP diluted EPS $2.26 vs $1.07.
Incyte appoints Thomas Tray as principal financial officer effective Sept 16, 2025
Thomas Tray, age 48, was appointed as principal financial officer, effective September 16, 2025.
Incyte CFO Christiana Stamoulis to step down effective September 16, 2025
CFO Christiana Stamoulis notified Incyte of her resignation to pursue another opportunity.
Incyte Q2 2025 revenue up 16% to $1.216B; raised Jakafi and oncology guidance
Total revenues $1.216B (+16% YoY); net product rev $1.059B (+17% YoY). GAAP EPS $2.04 diluted, vs $(2.04) loss a year ago.
Incyte appoints William J. Meury as President and CEO; Hervé Hoppenot retires
Hervé Hoppenot retired as President & CEO effective June 26, 2025; will serve as special advisor for up to one year.
Incyte shareholders approve 8.5M share increase in stock incentive plan, 1M in ESPP
Stock incentive plan amendment approved: shares increased from 66.5M to 75.0M, plan extended 5 years.
Incyte settles JAKAFI royalty dispute with Novartis; pays $280M vs $537M accrued
Settlement resolves litigation over royalty duration under 2009 Collaboration and License Agreement.
Incyte Q1 2025 revenues up 20% to $1.05B; Jakafi guidance raised
Total revenues $1,053M (+20% YoY); product rev $922M (+26%); GAAP diluted EPS $0.80; Non-GAAP $1.16.
Incyte Q4 2024 revenue $1.18B (+16% YoY), guides 2025 Jakafi $2.93-2.98B, Opzelura $630-670M
Q4 total revenues $1.18B (+16% YoY); full year $4.24B (+15%). GAAP diluted EPS $1.02 (Q4), $0.15 (FY); Non-GAAP $1.43 (Q4), $1.08 (FY).
Incyte EVP North America Barry Flannelly retires; successor starts Jan 6
Barry P. Flannelly, EVP General Manager North America, retired effective Jan 6, 2025.
Incyte Q3 2024 revenues up 24% to $1.14B; Jakafi guidance raised
Total revenues $1.138B (+24% YoY); Jakafi net revenue $741M (+16%); Opzelura $139M (+52%).
Q2 net loss $445M; revs up 9% to $1.04B; Jakafi guidance raised; $2B buyback completed
Total revenues $1,044M (+9% YoY); Jakafi $706M (+3%), Opzelura $122M (+52%).
Incyte extends revolving credit facility maturity to June 2027
Maturity of revolving credit facility extended from Aug 18, 2024 to June 28, 2027.
All nine director nominees elected with at least 171M votes for (89.6% to 99.4% of votes cast).
Incyte commences $1.672B Dutch auction tender offer, agrees to buy $328M from Baker Entities
Incyte commences modified Dutch auction tender offer to repurchase up to $1.672 billion of common stock at $52-$60 per share.
Incyte Q1 revenues $881M (+9% YoY), GAAP EPS $0.75; to acquire Escient for $750M
Revenue $881M (+9% YoY); GAAP net income $169.5M, diluted EPS $0.75.
Incyte reports FY23 revenue $3.7B (+14%), Jakafi $2.59B, Opzelura $338M; guides 2024
Total FY23 net product and royalty revenue $3.7B (+14% Y/Y); Q4 total revenue topped $1B for first time.
Incyte Q3 2023 revenues up 12% to $919M; Jakafi guidance tightened to $2.59-2.62B
Total GAAP revenues of $919M (+12% YoY); GAAP net income $171M ($0.76 diluted EPS).
Incyte EVP & General Counsel Maria Pasquale to retire Nov 1, 2023
Maria E. Pasquale notified Incyte of her retirement effective November 1, 2023.
Incyte Q2 product revenue up 25% to $827M; raises Jakafi guidance; CSO departs
Total net product revenue $827M (+25% YoY); Jakafi $682M (+14%), Opzelura $80M (+384%).
Incyte shareholders approve 12.5M share increase in stock incentive plan
Stockholders approved amendment to 2010 Stock Incentive Plan, increasing shares by 12,500,000 to 66,453,475.
Incyte appoints Dr. Pablo J. Cagnoni as President, R&D, effective June 5, 2023
Board approved appointment of Pablo J. Cagnoni, M.D. as President, Research and Development on May 4, 2023.
Incyte Q1: Jakafi rev $580M (+7%); Opzelura $57M (+343%); raises Jakafi FY guidance to $2.55-2.63B
Total net product revenues $693M (+14% YoY); total GAAP revenues $808.7M (+10% YoY).
Incyte reports FY2022 revenue $3.4B (+14%); Jakafi up 13%; provides 2023 guidance
FY2022 total revenues $3.39B (+14% YoY), net product rev $2.75B (+18%); GAAP diluted EPS $1.52, non-GAAP $2.78.
Incyte Q3 product rev $713M (+20%); Jakafi guidance raised to $2.38-2.40B; Opzelura $38M
Total product revenues $713M (+20% YoY); Jakafi $620M (+13%); Opzelura $38M ($0 prior year).
Incyte elects Susanne Schaffert, former Novartis Oncology President, to board
Effective Oct 1, 2022, board increased to nine members, elected Susanne Schaffert.
Incyte Q2 total revenues up 29% to $911M; raises Jakafi guidance bottom end
Total revenues $911M (+29% YoY); product revenues $664M (+15% YoY).
Incyte annual meeting results: all board nominees elected, Say-on-Pay and auditor ratified
All eight director nominees elected; for votes ranged from 171.6M (Clancy) to 186.3M (Harrigan).
Incyte Q1 2022 revenue $733M (+21%); Jakafi guidance raised; Opzelura uptake strong
Total product & royalty revenues $728M (+20% YoY); GAAP net income $38M ($0.17 EPS); non-GAAP net income $123M ($0.55).
Director Wendy L. Dixon to retire from Incyte board at 2022 annual meeting
Wendy L. Dixon notified Incyte on April 18, 2022, of her retirement.
Incyte Q4 product/royalty rev $813M (+20%); non-GAAP EPS $0.10; 2022 Jakafi guidance $2.3-2.4B
Jakafi net product revenues $592M in Q4 (+15%) and $2.135B for FY21 (+10%).
Incyte names Thomas Tray as Principal Accounting Officer; Paul Trower to retire March 11, 2022
Paul Trower notified Incyte of retirement as Division VP, Finance and Principal Accounting Officer effective March 11, 2022.
Incyte reports 3 product complaints for Opzelura cream; suspends affected batches
Three product complaints received for Opzelura (ruxolitinib) cream related to texture.
Incyte Q3 GAAP net income $181.7M vs loss, revenue $812.9M (+31%); multiple approvals
Total product & royalty revenues $777.987M, +25% YoY; Jakafi $547.373M (+12%).
Incyte elects Otis W. Brawley, M.D. to board effective Sept 27, 2021
Board size increased to nine; Dr. Brawley elected as director effective September 27, 2021.
Incyte enters $500M unsecured three-year revolving credit facility
Facility of $500M with J.P. Morgan as admin agent; matures in three years.
Incyte reports Q2 2021 product revenue $696M (+17% YoY); GAAP net income $149M vs $290M prior year
Jakafi net product revenues $529M (+12% YoY); total product and royalty revenues $696M (+17%).
On January 6, 2025, Barry P. Flannelly, Executive Vice President, General Manager, North America of Incyte Corporation (the “Company”), announced his retirement from the Company and stepped down from that role on that date, effective with the commencement of employment of his successor.
On September 8, 2023, Maria E. Pasquale, Executive Vice President, General Counsel and Corporate Secretary of Incyte Corporation (the “Company”), notified the Company of her intention to retire effective November 1, 2023.
Election of Directors Effective October 1, 2022, the Board of Directors of Incyte Corporation (the “Company”) increased the number of authorized members of the Board of Directors of the Company to nine and elected Susanne Schaffert, Ph.D., a member of the Board of Directors of the Company.
On April 18, 2022, Wendy L. Dixon notified Incyte Corporation (the “Company”) that she will be retiring from the Company’s Board of Directors, effective at the time of the Company’s 2022 Annual Meeting of Stockholders.
Effective March 11, 2022, the board of directors of the Company appointed Thomas Tray, age 44, as the Company’s Vice President, Finance and Chief Accounting Officer (Principal Accounting Officer).
On January 10, 2022, Paul Trower notified Incyte Corporation (the “Company”) of his intention to retire as Division Vice President, Finance and Principal Accounting Officer of the Company effective March 11, 2022.
Effective September 27, 2021, the Board of Directors of Incyte Corporation (the “Company”) increased the number of authorized members of the Board of Directors of the Company to nine and elected Otis W. Brawley, M.D., a member of the Board of Directors of the Company.
Max materiality 0.90 · Median 0.75 · Most common event earnings